Table 1 Clinical and pathologic characteristics of breast cancer patients receiving NAC.
Characteristics | R (N = 161) | NR (N = 47) | All (N = 208) |
|---|---|---|---|
Age (year) | 50 ± 12 | 52 ± 11 | 51 ± 11 |
Menopause | |||
 Postmenopausal (%) | 41 | 36 | 40 |
 Premenopausal (%) | 47 | 57 | 52 |
 Perimenopausal (%) | 12 | 7 | 8 |
Initial tumour size (cm) | 5.2 ± 2.8 | 5.0 ± 2.6 | 5.0 ± 2.7 |
Histology | |||
 IDC (%) | 93 | 83 | 92 |
 ILC (%) | 3 | 9 | 4 |
 IMC (%) | 4 | 8 | 4 |
Group Stage | |||
 Stage II (%) | 50 | 61 | 52 |
 Stage III (%) | 48 | 37 | 46 |
 Not reported (%) | 2 | 2 | 2 |
Tumour Grade | |||
 Grade I (%) | 6 | 9 | 5 |
 Grade II (%) | 34 | 43 | 38 |
 Grade III (%) | 50 | 47 | 49 |
 Not reported (%) | 10 | 1 | 8 |
Molecular Subtype | |||
 ERBB2 + (%) | 14 | 0 | 11 |
 Triple Negative (%) | 25 | 26 | 25 |
 LuminalA (%) | 36 | 64 | 42 |
 LuminalB (%) | 25 | 11 | 22 |
Treatment | |||
 ACT (%) | 53 | 68 | 59 |
 FECD (%) | 30 | 23 | 28 |
 Others (%) | 17 | 9 | 13 |
Residual tumour size (cm) | 1.8 ± 2.2 | 5.9 ± 4.5 | 2.7 ± 3.4 |
